Peer-reviewed veterinary case report
Carboplatin chemo after spleen removal for dog hemangiosarcoma
By Faulhaber, Erica A et al.·Published in Journal of veterinary internal medicine·2021·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with splenic hemangiosarcoma (a type of cancer) underwent surgery to remove their spleens and then received either carboplatin or doxorubicin chemotherapy. The dogs treated with carboplatin had a median survival time of about 160 days, while those on doxorubicin survived around 139 days. Interestingly, dogs whose monocyte counts (a type of white blood cell) decreased after surgery had a much better survival time of 265 days compared to those with increased counts, who only lived about 66 days. Carboplatin may be a good option for dogs that can't tolerate doxorubicin.
People also search for: dog hemangiosarcoma treatment · carboplatin for dogs cancer · doxorubicin side effects in dogs
Abstract
BACKGROUND: Doxorubicin-based chemotherapy after splenectomy remains the standard of care for hemangiosarcoma in dogs, but prognosis is generally poor. HYPOTHESIS/OBJECTIVES: To determine clinical outcome with carboplatin chemotherapy after splenectomy compared to doxorubicin-based protocols. A secondary objective was to determine if peripheral monocyte count was associated with prognosis. ANIMALS: Medical data from 40 dogs with histopathologically confirmed stage I or II hemangiosarcoma treated with splenectomy and carboplatin (n = 18) or doxorubicin-based protocols (n = 22) were evaluated. METHODS: Retrospective study. Statistical associations were assessed using the Kaplan-Meier method for survival times and log rank analysis for differences in survival time. Demographic information and survival times were obtained via medical records. Blood monocyte counts before and after surgery were documented. RESULTS: Median survival times were 160 days (48 to >559) and 139 days (54-975), for dogs in the carboplatin (n = 18) and doxorubicin (n = 22) groups respectively (P = .82, hazards ratio [HR] [95% CI] = 1.075 [0.56-2.07]). The median survival time for dogs whose monocyte counts decreased between splenectomy and chemotherapy initiation was 265 days, compared to 66 days for dogs with increased monocytes (P = .002, HR [95% CI] = 4.17 [1.21-14.39]). CONCLUSIONS AND CLINICAL IMPORTANCE: Carboplatin could be considered as an alternative in cases where doxorubicin might be contraindicated. Increasing postoperative peripheral monocyte counts might be associated with a poorer prognosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34227148/